UniProtKB/SwissProt variant VAR

Variant information

Variant position:

252

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LP/P [Disclaimer]

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Leucine (L) to Proline (P) at position 252 (L252P, p.Leu252Pro).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic.

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

-3

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In LFS; germline mutation and in sporadic cancers; somatic mutation.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs121912653 [ dbSNP | Ensembl ]

Sequence information

Variant position:

252

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

393

The length of the canonical sequence.

Location on the sequence:

IHYNYMCNSSCMGGMNRRPI L TIITLEDSSGNLLGRNSFEV

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         IHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEV

                              IHYNYMCNSSCMGGMNRRPILTIITLEDSSGNVLGRNSFEV

Rhesus macaque                IHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEV

Mouse                         IHYKYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEV

Rat                           IHYKYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEV

Pig                           IHYNFMCNSSCMGGMNRRPILTIITLEDASGNLLGRNSFEV

Bovine                        IHYNFMCNSSCMGGMNRRPILTIITLEDSCGNLLGRNSFEV

Rabbit                        IHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEV

Sheep                         IHYNFMCNSSCMGGMNRRPILTIITLEDSRGNLLGRSSFEV

Cat                           IHYNFMCNSSCMGGMNRRPIITIITLEDSNGKLLGRNSFEV

Chicken                       VLYNFMCNSSCMGGMNRRPILTILTLEGPGGQLLGRRCFEV

Xenopus laevis                VLYNYMCNSSCMGGMNRRPILTIITLETPQGLLLGRRCFEV

Zebrafish                     VLLNYMCNSSCMGGMNRRPILTIITLETQEGQLLGRRSFEV

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 393	Cellular tumor antigen p53
DNA binding	102 – 292
Region	1 – 320	Interaction with CCAR2
Region	100 – 370	Interaction with HIPK1
Region	100 – 300	Required for interaction with ZNF385A
Region	116 – 292	Interaction with AXIN1
Metal binding	238 – 238	Zinc
Metal binding	242 – 242	Zinc
Modified residue	269 – 269	Phosphoserine; by AURKB
Mutagenesis	248 – 248	R -> S. Does not induce SNAI1 degradation.
Mutagenesis	269 – 269	S -> A. Abolishes phosphorylation.
Mutagenesis	269 – 269	S -> E. Inhibits strongly its transcriptional activity.
Beta strand	251 – 258

Literature citations

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
Malkin D.; Li F.P.; Strong L.C.; Fraumeni J.F. Jr.; Nelson C.E.; Kim D.H.; Kassel J.; Gryka M.A.; Bischoff F.Z.; Tainsky M.A.; Friend S.H.;
Science 250:1233-1238(1990)
Cited for: VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P04637: Variant p.Leu252Pro